STAT+: CMS wants more drugmakers to join Medicaid ‘most-favored nations’ pilot

UniQure's plans to seek approval for its Huntington’s disease treatment remain blocked by the FDA. The agency has expressed skepticism regarding the therapy's efficacy, with a senior official stating that the FDA is "not convinced" the treatment provides any benefit to patients. This conclusion is based on the existing clinical data reviewed by the FDA, which indicates that the experimental therapy does not demonstrate a meaningful advantage for those suffering from Huntington's disease. The ongoing situation has led to a notable feud between UniQure and the FDA, as the company attempts to navigate the regulatory landscape to gain approval for its product. The FDA's stance reflects a broader scrutiny of experimental therapies and their claimed benefits, emphasizing the importance of robust clinical evidence in the approval process. In addition to the UniQure situation, the news also highlights a new Medicaid pilot program aimed at encouraging more drugmakers to participate in the "most-favored nations" initiative. This program is part of broader efforts by the Centers for Medicare & Medicaid Services (CMS) to manage drug pricing and ensure that patients have access to effective treatments. Overall, the developments surrounding UniQure's Huntington’s therapy and the new Medicaid pilot program underscore the complexities and challenges faced by biotech companies in the current regulatory environment.